Claire Poulard
Directeur/Bestuurslid bij Newronika SRL
Oorsprong van het eerstegraads netwerk van Claire Poulard
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Omnes Capital SAS /Venture/
 Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes Capital SAS /Venture/ is a Venture Capital firm, a subsidiary of Omnes Capital SAS founded in 1999. Omnes Capital /Venture/ is headquartered in Paris.
12
| Operating Division | Investment Managers | 12 |
Antabio SAS
 Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Newronika SRL
 Newronika SRL Medical SpecialtiesHealth Technology Newronika SRL manufactures medical and electro-medical equipment and appliances. It offers new adaptive deep brain stimulation systems for movement disorders (DBS); methods and devices for transcranial direct current stimulation (tDCS) represent the non-invasive neuromodulation activity. The company was founded by Priori Alberto and Lorenzo Rossi and is headquartered in Milan, Italy.
5
| Holding Company | Medical Specialties | 5 |
Algotherapeutix SAS
 Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018.
5
| Holding Company | Medical Specialties | 5 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Claire Poulard via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
Horama SA
 Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Chairman Director/Board Member | |
Eye Tech Care SA
 Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
| SUPERSONIC IMAGINE | Medical Specialties | Director of Finance/CFO Director/Board Member | |
| École des Hautes Études Commerciales de Paris | College/University | Graduate Degree Undergraduate Degree | |
Enterome SA
 Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Amakem NV
 Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Tissium SA
 Tissium SA BiotechnologyHealth Technology Tissium SA engages in the development and commercialization of biodegradable sealants and adhesives for invasive surgery. It offers biomimetic wound closure solutions. The company was founded by Bernard J. Gilly, Robert S. Langer, Christophe Bancel, Jeff Karp, Jacques Marescaux, Maria Pereira, and Patrick Houvet in 2013 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Director/Board Member | |
| EOS IMAGING | Medical Specialties | Director/Board Member Director/Board Member | |
| POXEL | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Themis Bioscience GmbH
 Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| ADVICENNE | Pharmaceuticals: Generic | Director/Board Member | |
Acacia Pharma, Inc.
 Acacia Pharma, Inc. Medical DistributorsDistribution Services Part of Eagle Pharmaceuticals, Inc., Acacia Pharma, Inc. distributes pharmaceutical products. The company is based in Dover, DE. | Medical Distributors | President | |
Novartis Seeds AG
 Novartis Seeds AG Chemicals: AgriculturalProcess Industries Part of Novartis AG, Novartis Seeds AG is a company that manufactures agro-chemical products. The company is based in Novartis, Switzerland. | Chemicals: Agricultural | Chief Tech/Sci/R&D Officer | |
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | Pharmaceuticals: Major | President | |
BrainVectis SAS
 BrainVectis SAS BiotechnologyHealth Technology BrainVectis SAS provides gene therapy services. It develops gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain to restore cholesterol metabolism. The company was founded by Nathalie Cartier-Lacave and Jérôme Becquart in 2015 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
| CADENCE PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Bradley University | College/University | Undergraduate Degree | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ACACIA PHARMA GROUP PLC | Pharmaceuticals: Other | Chairman | |
| Harvard Business School | College/University | Masters Business Admin | |
Acacia Pharma Ltd.
 Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Outpost Medicine Ltd.
 Outpost Medicine Ltd. Pharmaceuticals: MajorHealth Technology Part of Outpost Medicine, Inc., Outpost Medicine Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The company is based in London, UK. The company was founded in 2016. Scott A. Byrd has been the CEO of the company since 2017. | Pharmaceuticals: Major | Chief Executive Officer | |
Outpost Medicine, Inc.
 Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | Pharmaceuticals: Major | Chief Executive Officer | |
Sudo Biosciences, Inc.
 Sudo Biosciences, Inc. Information Technology ServicesTechnology Services Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd. | Information Technology Services | Chief Executive Officer | |
| SOCIÉTÉ GÉNÉRALE | Regional Banks | Public Communications Contact | |
| BOURSORAMA | Investment Banks/Brokers | Chairman | |
GlaxoSmithKline AG
 GlaxoSmithKline AG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline AG is a Swiss company. | Pharmaceuticals: Major | Sales & Marketing | |
| SMITH & NEPHEW PLC | Medical Specialties | Corporate Officer/Principal | |
| SYNGENTA | Chemicals: Agricultural | Corporate Officer/Principal | |
| BIOM'UP | Medical Specialties | Director/Board Member | |
LimFlow SA
 LimFlow SA Medical SpecialtiesHealth Technology LimFlow SA develops and offers medical devices which transformes the treatment of critical limb Ischemi. The firm?s proprietary and CE marked technology is a novel and purely percutaneous therapy for ?no-option? CLI patients. The company was founded by Martin T. Rothman in 2012 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member | |
| TXCELL | Miscellaneous Commercial Services | Director/Board Member | |
GamaMabs Pharma SA
 GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | Medical/Nursing Services | Director/Board Member | |
Step Pharma SAS
 Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Pharmaceuticals: Major | Director/Board Member | |
| École Centrale Paris | College/University | Undergraduate Degree | |
| GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member | |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member | |
| NH THERAGUIX SAS | Pharmaceuticals: Major | Director/Board Member | |
ADEMTECH SA
 ADEMTECH SA Miscellaneous Commercial ServicesCommercial Services ADEMTECH SA specializes in developing and manufacturing magnetic nanoparticles for diagnostic and scientific research applications. The firm produces magnetic nanoparticles for concentration, separation, purification, microfluidic device integration and identification of molecules and specific cells. The company was founded in 2000 and is headquartered in Pessac, France. | Miscellaneous Commercial Services | Director/Board Member | |
CorWave SA
 CorWave SA Medical SpecialtiesHealth Technology CorWave SA develops and manufactures blood pumps. The company was founded in 2011 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member | |
| SENSORION | Pharmaceuticals: Major | Director/Board Member | |
| Ghent University | College/University | Doctorate Degree | |
BPIFrance Investissement SAS
 BPIFrance Investissement SAS Investment ManagersFinance BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development. | Investment Managers | Private Equity Analyst |
Statistieken
Internationaal
| Frankrijk | 31 |
| Verenigde Staten | 9 |
| Verenigd Koninkrijk | 6 |
| Zwitserland | 4 |
| België | 3 |
Sectoraal
| Health Technology | 32 |
| Consumer Services | 8 |
| Finance | 5 |
| Health Services | 3 |
| Process Industries | 3 |
Operationeel
| Director/Board Member | 130 |
| Corporate Officer/Principal | 32 |
| Chief Executive Officer | 20 |
| Private Equity Investor | 17 |
| Chairman | 16 |
Sterkste connecties
| Insiders | |
|---|---|
| Bruno Montanari | 30 |
| Hugues le Bret | 25 |
| Alexia Perouse | 20 |
| Thibaut Roulon | 18 |
| Michel de Lempdes | 16 |
| Claudio Giuliano | 15 |
| Stéphane Thiroloix | 12 |
| Scott A. Byrd | 11 |
| Benedikt Timmerman | 11 |
| Edmund Harrigan | 10 |
| Gordon Waldron | 8 |
| Renaud Poulard | 7 |
| Lothar Krinke | 6 |
| Carlo Sanfilippo | 6 |
| Helmuth van Es | 5 |
- Beurs
- Insiders
- Claire Poulard
- Bedrijfsconnecties
